Skip to main content
. Author manuscript; available in PMC: 2016 Sep 8.
Published in final edited form as: Biol Blood Marrow Transplant. 2016 Jan 13;22(5):825–833. doi: 10.1016/j.bbmt.2016.01.003

Figure 5. pTFH cells are significantly depleted in patients with ongoing cGVHD.

Figure 5

(A) pTFH counts in patients without cGVHD (n=21) compared to patients with cGVHD (limited or extensive) (n= 19) at 1 year post-transplantation (43.4 ± 4.0 vs 14.4 ± 3.9 cells/ul, *** p <0.0001. Mann-Whitney t-Test.). (B) Quantification of pTFH cells in patients without versus with any cGVHD grouped by donor source (MRD, 53.5 ± 4.3 vs 30.1 ± 5.6, ** p=0.007; UCB 38.4 ± 5.2 vs 3.1 ± 1.2, ***p < 0.0001). (C) Absolute CD4 counts in MRD and UCB recipients in patients with or without cGVHD (MRD, 384.3 ± 47.9 vs 436.6 ± 82.2, NS, p=0.61; UCB 364.9 ± 38.4 vs 258.5 ± 81.0, NS, p=0.21). (D-H) CD4 T cells from peripheral blood were gated from the Live CD3+ population following stimulation with SEB. Subsequently, CXCR5+ and CXCR5− populations within the CD4+ subset were analyzed for expression of CD40L and multiple cytokines including IL-21, IL-2, IL-17, IFNγ, and TNFα. Graphs B-F show compiled data for CXCR5+ cells that coexpress CD40L and B) IL-21, C) IL-2, D) IL-17, E) IFNy, or F) TNFα. Differences between donors (B-F) were non-significant.